... NEW YORK Aug. 19 2014 iReach/ ...Dr. Treado's poster entitled Development of in vitro Diagnostics for... I am very excited to present our findings at 2014 SPEC said span i...SPEC 2014 is an international conference series aiming to bring togeth...

Dr. Treado's poster entitled, "Development of in vitro Diagnostics for Detection of Colorectal Cancer Using Raman Molecular Imaging" will be discussed during the conference poster session on Tuesday, August 19, 2014 from 6:30 – 8:00pm. The scientific poster presents the results of a study performed by scientists at ChemImage, in collaboration with urology and gastroenterology clinicians, on the development of in vitro diagnostic (IVD) Raman assays focused on colorectal cancer detection. The results of these ongoing clinical studies will be presented including discussion of the study design, the underlying basis of discrimination and advantages provided by RMI.

"I am very excited to present our findings at 2014 SPEC," said Patrick J. Treado, Chief Technology Officer at ChemImage. "I look forward to sharing the results of our research with thought leaders in the Raman spectroscopy community."

SPEC 2014 is an international conference series aiming to bring together clinicians and scientists who have joined forces in the quest for novel biomedical applications of Infrared and Raman spectroscopy to improve patient care. Due to its unique fingerprinting capability, Raman spectroscopy plays a significant role in histopathology, cytology, biopsy targeting, surgical targets, and treatment monitoring and drug studies. The conference highlights further advances in state of the art and emerging biomedical applications of Raman Spectroscopy, while critically reviewing the challenges in the context of other emerging technologies.

ChemImage's headquarters are located in Pittsburgh, PA, where it pioneers research and development, as well as providing engineering and manufacturing which develops innovative products for the global marketplace.

(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...

(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...

(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying ... Va. "I thought that if the nebulizer had a more child-friendly design, then children ... , He developed the patent-pending NEBY to avoid the need to deliver medication via ...